Inhibrx Biosciences, Inc. (INBX) has a negative trailing P/E of -7.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 19.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -12.96%, forward earnings yield 5.12%.
Criteria proven by this page:
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -91.2 | 0.00 | -81.55 | 113.11 | - |
| 2017 | -30.5 | -0.16 | -20.64 | 74.71 | 0.23% |
| 2018 | -17.9 | -0.26 | -9.69 | 74.48 | 0.15% |
| 2019 | -14.7 | -0.65 | -8.06 | 82.93 | - |
| 2020 | -11.0 | -0.10 | 11.04 | 65.03 | - |
| 2021 | -20.3 | 0.72 | 31.69 | 232.97 | - |
| 2022 | -6.8 | -0.10 | 17.02 | 450.85 | - |
| 2023 | -7.4 | -0.18 | 41.17 | 994.97 | - |
| 2024 | 0.1 | 0.00 | 1.67 | 1,114.64 | 5.52% |
| 2025 | -8.7 | 0.08 | 153.07 | 941.13 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.23 | $6.67M | $-8.27M | -124% |
| 2017 | $-0.68 | $7.95M | $-19.44M | -244.6% |
| 2018 | $-1.15 | $7.5M | $-31.16M | -415.5% |
| 2019 | $-1.41 | $9.09M | $-51.4M | -565.3% |
| 2020 | $-2.99 | $12.81M | $-75.64M | -590.5% |
| 2021 | $-2.15 | $7.13M | $-81.77M | -1147.6% |
| 2022 | $-3.62 | $2.18M | $-145.23M | -6667.9% |
| 2023 | $-5.12 | $1.8M | $-241.36M | -13408.9% |
| 2024 | $112.62 | $200K | $1.69B | 843786% |
| 2025 | $-9.04 | $1.3M | $-140.06M | -10773.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-5.46 | $-5.46 – $-5.46 | $4.3M | $4.3M – $4.3M | 1 |
| 2027 | $-2.79 | $-2.79 – $-2.79 | $60.33M | $60.33M – $60.33M | 1 |
| 2028 | $-0.95 | $-0.95 – $-0.95 | $97.64M | $97.64M – $97.64M | 1 |
| 2029 | $0.22 | $0.22 – $0.22 | $129.25M | $129.25M – $129.25M | 1 |
| 2030 | $1.75 | $1.75 – $1.75 | $187.23M | $187.23M – $187.23M | 1 |
